Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XTR004 PET vs MIBI SPECT myocardial perfusion imaging in borderline coronary stenosis
CTR20244418Phase 2Active
- Sponsor
- Sinotau Pharmaceutical Group
- Start
- Dec 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 18F-FMPP in coronary arteriosclerosis and cardiac ischemia, sponsored by Sinotau Pharmaceutical Group. Primary endpoint: Vessel-level diagnostic certainty of XTR004 PET vs MIBI SPECT myocardial perfusion imaging. Started Dec 2024; status: active.
02
Drugs
18F-FMPP
03
Conditions
coronary arteriosclerosiscardiac ischemia
Beyond the preview
Go deeper on CTR20244418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244418.